Baudax Bio

Corporate

Presentation

September 2021

1

Forward Looking Statements

This presentation contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio's expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words "anticipate," "believe," "estimate," "may," "upcoming," "plan," "target," "goal," "intend," and "expect," and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio's performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, risks related to the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, Baudax Bio's ability to maintain regulatory approval for ANJESO, Baudax Bio's ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies; Baudax Bio's ability and that of Baudax Bio's third party manufacturers to successfully scale-up the commercial manufacturing process for ANJESO, Baudax Bio's ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio's ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio's ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio's ability to comply with the financial and other covenants under its credit facility, Baudax Bio's ability to manage costs and execute on its operational and budget plans, the accuracy of Baudax Bio's estimates of the potential market for ANJESO, Baudax Bio's ability to achieve its financial goals; and Baudax Bio's ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect Baudax Bio's business and future results included in Baudax Bio's filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.

2

Company Highlights

  • ANJESO® (meloxicam) injection
    • Product launched 2020
    • Approved for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics*
    • Significant potential commercial opportunity
  • Additional pipeline candidates in clinical stage development for acute care settings
  • Baudax financial position
    • Cash, cash equivalents and short-term investments as of 6/30/21 : $37.6 Million
  • Experienced management team with significant commercial, development, and regulatory experience

* Limitation of Use: Because of delayed onset of analgesia, ANJESO® alone is not recommended for use when rapid onset of analgesia is required.

3

Please see Important Safety Information including BOXED WARNING at the end of presentation.

Full Prescribing Information at www.ANJESO.com

Experienced Commercial Management &

Launch Leadership Team

Gerri Henwood - President and CEO

Founded Recro Pharma (REPH), Auxilium Pharmaceuticals (AUXL - NASDAQ then Endo) and IBAH (NASDAQ then Omnicare); GSK

Richard Casten - Chief Financial Officer

25 years diversified financial experience - Lupin Pharmaceuticals (LUPIN - NSE), Endo International (ENDP - NASDAQ), Campbell Soup Company (CPB - NYSE), Ernst & Young LLP

Jyrki Mattila, MD, PhD -EVP, Business Development

Over 30 years of Pharma executive leadership and business development experience -Lipocine, iCeutica, Auxilium, Orion Pharma

Greg Gangemi - Chief Commercial Officer and Sr. Vice President

Over 25 years of industry, launch and operations experience - Recro, Sepracor/Sunovion, Cubist, Ferring and Ocular Therapeutix

Janeese Carter - Vice President, Marketing

Over 15 years of marketing, market research, new business strategy, and sales - Recro Pharma, CSL Behring, Pfizer/Wyeth

Paul Baddeley - Executive Director, Commercial Operations

4

20 years of industry and consulting experience in commercial operations & analytics - Recro, Collegium,

IMS Health, Endo

Commercial Opportunity

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Baudax Bio Inc. published this content on 13 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 September 2021 14:21:05 UTC.